Specific Biologics Inc.

Specific Biologics Inc. , located in Canada, specializes in innovative gene editing technologies, notably its proprietary Dualase platform, designed to enhance precision in genetic modifications for complex disorders. Founded in 2017 in Toronto, Canada, Specific Biologics Inc. develops advanced gene editing solutions utilizing its Dualase platform.

The firm has completed two funding deals, with the latest in October 2023, indicating its ongoing strategy to advance its technology. Co-founders Brent Stead and Odi Israel have extensive backgrounds in biotechnology. Specific Biologics Inc. (SBI) specializes in developing innovative gene editing technologies, with a core focus on its proprietary platform known as Dualase.

This technology employs a dual-cleaving nuclease that cuts DNA at two sites, generating non-compatible ends intended to improve the precision of genetic modifications. By leveraging the cell's natural DNA repair mechanisms, Dualase facilitates either defined length deletions or enhanced repair efficiency, allowing SBI to target genetic diseases previously deemed untreatable. The end users of this technology include researchers and clinicians in academic and industrial settings, with potential applications across a broad range of genetic disorders. SBI aims to introduce this technology into markets in North America and Europe, targeting institutions and healthcare providers seeking advanced gene editing solutions.

Specific Biologics generates revenue through strategic partnerships and collaborations rather than direct consumer sales. The company engages with biotech firms, research institutions, and healthcare providers to license its gene editing technology, particularly the Dualase platform. These transactions take the form of licensing agreements, where clients pay fees for access to the technology, potentially structured as ongoing royalties based on the success of clinical applications. Additionally, SBI may seek funding through grants and development awards, exemplified by its recent therapeutic development award from the Cystic Fibrosis Foundation.

The company’s collaborations with industry leaders and its focus on advancing gene editing capabilities position it favorably within the biotechnology sector. In October 2023, Specific Biologics Inc. raised an undisclosed amount of venture funding from returning investors Lumira Ventures and adMare Bioinnovations. The company will use this funding to advance the preclinical development of therapeutics based on its Dualase platform gene editors, specifically targeting liver, ocular, and CNS diseases, as well as cystic fibrosis.

SBI is also planning to expand into North American and European markets, focusing on healthcare institutions and providers to enhance its reach.